For the quarter ending 2025-09-30, BOLT made $2,169,000 in revenue. -$7,148,000 in net income. Net profit margin of -329.55%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Collaboration revenue | 2,169,000 | 1,804,000 | 1,222,000 | 2,183,000 |
| Research and development | 6,535,000 | 7,498,000 | 9,512,000 | 14,561,333.333 |
| General and administrative | 3,337,000 | 3,516,000 | 3,825,000 | 4,886,000 |
| Impairment charges | - | - | - | 367,250 |
| Restructuring charges | 0 | 0 | - | 835,750 |
| Total operating expense | 9,872,000 | 11,014,000 | 13,337,000 | 21,051,333.333 |
| Loss from operations | -7,703,000 | -9,210,000 | -12,115,000 | -18,868,333.333 |
| Interest income, net | 477,000 | 599,000 | 1,053,000 | 1,718,916.667 |
| Other income | 82,000 | 50,000 | 22,000 | 1,168,750 |
| Total other income, net | 559,000 | 649,000 | 1,075,000 | 2,887,666.667 |
| Net loss | -7,144,000 | -8,561,000 | -11,040,000 | -15,980,666.667 |
| Net unrealized (loss) gain on marketable securities | -4,000 | -46,000 | -57,000 | -63,000 |
| Comprehensive loss | -7,148,000 | -8,607,000 | -11,097,000 | -16,043,666.667 |
| Earnings per share, basic, total | -3.72 | -4.46 | -0.29 | -0.417 |
| Earnings per share, diluted, total | -3.72 | -4.46 | -0.29 | -0.417 |
| Weighted average common shares outstanding - basic | 1,919,441 | 1,917,629 | 38,339,697 | -22,350.333 |
| Weighted-average shares outstanding, diluted | 1,919,441 | 1,917,629 | 38,339,697 | -22,350.333 |
Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc. (BOLT)